ArticleLipids in health and disease2025
Association between volatile organic compounds in urine and dyslipidemia: findings based on analysis of NHANES data.
Article in Lipids in health and disease, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundEvidence linking urinary metabolites of volatile organic compounds (UMVOCs) to dyslipidemia remains limited and scarce. This research sought to thoroughly clarify the UMVOCs-dyslipidemia associations and evaluate the inflammation's mediating effect in this association.
methodsNationally representative data (from 6,962 enrolled participants) obtained from the National Health and Nutrition Examination Survey (NHANES) formed the basis of this analysis. We applied weighted logistic regression models for the assessment of relationship between individual UMVOC exposure and dyslipidemia, and weighted quantile sum (WQS) regression for the evaluation of the impact of co-exposure to multiple mixed UMVOCs on dyslipidemia. We performed mediation analysis for investigation into inflammation's role as a mediator, with white blood cell count (WBC), neutrophil count (NC), as well as lymphocyte count (LC) incorporated for the evaluation of their respective contributions to the overall mediation effect.
resultsUrinary concentrations of 34MHA and CEMA were positively linked to dyslipidemia, with respective odds ratios (OR) of 1.10 (95% confidence interval [CI]: 1.00-1.21) and 1.21 (95% CI: 1.08-1.35). Furthermore, through WQS regression analysis, we found that exposure to a mixture of 16 UMVOCs was significantly and positively linked to dyslipidemia (OR = 1.14, 95% CI: 1.04-1.24, P = 0.002), with CEMA making the greatest relative contribution (29.75%). Mediation analysis demonstrated that WBC, NC, and LC partially mediated the association between CEMA and dyslipidemia, accounting for 10.35%, 6.54%, and 6.52% of the total mediation effects, respectively (all P < 0.001).
conclusionSimultaneous exposure to multiple UMVOCs is positively and significantly linked to the prevalence of dyslipidemia, with inflammation partially mediating this relationship. Our findings suggest that prolonged or high-level exposure to UMVOCs may contribute to dyslipidemia through inflammatory pathways, underscoring the potential metabolic health risks posed by environmental pollutants.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.